-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $60 Price Target

Benzinga·03/13/2026 13:12:16
Listen to the news
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $60 price target.